Sign inJoin waitlistJoin the waitlist

SG

Sergio Giralt

Deputy Division Head, Division of Hematologic Malignancies · New York Presbyterian Hospital

Credentials: · · · · ·

History

Division of Hematologic Malignancies · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present

Hematology and Medical Oncology
1987–1990
Good Samaritan Hospital
1984–1987
Central University of Venezuela
1980–1984

Research

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Science Translational Medicine · 2014 · 2,062 citations
Defining the intensity of conditioning regimens: working definitions
Biology of Blood and Marrow Transplantation · 2009 · 1,558 citations
Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma…
British Journal of Haematology · 1998 · 1,211 citations

Richard Champlin
232 papers
MP
Miguel-Angel Perales
180 papers
Gunjan Shah
126 papers · 2 as a fellow
Issa Khouri
122 papers
Michael Scordo
118 papers · 4 as a fellow
Marcos de Lima
108 papers · 5 as a fellow
AJ
Ann Jakubowski
101 papers
HL
Heather Landau
99 papers
BA
Borje Andersson
89 papers
EP
Esperanza Papadopoulos
88 papers
PD
Parastoo Dahi
85 papers
PA
Paolo Anderlini
78 papers · 2 as a fellow

Grants

Immunobiology of Allogeneic Hematopoietic Cell Transplantation
National Cancer Institute · P01
Project lead · $2M · Sloan-Kettering Inst Can Research
1997–2025
MSKCC BMT CTN Renewal
National Heart, Lung, and Blood Institute · U10
Contact PI · $1.1M · Sloan-Kettering Inst Can Research
2001–2017
Mechanisms of Symptoms of Multiple Myeloma and Its Therapy
National Cancer Institute · P01
Project lead · $1.3M · University of Tx Md Anderson Can Ctr
2008–2014
Il-7 for Immune Recovery After Hematopoietic Allografts
National Heart, Lung, and Blood Institute · U01
Contact PI · $234K · Sloan-Kettering Inst Can Research
2001–2011

Clinical trials

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Principal investigator · Completed · Phase 2
Medical College of Wisconsin
2022–2025
Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
Principal investigator · Completed
Memorial Sloan Kettering Cancer Center
2017–2023
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Principal investigator · Active not recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2015–2026
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Principal investigator · Completed · Phase 1, Phase 2
Memorial Sloan Kettering Cancer Center
2013–2016